Pyrophosphate-modified liposomes for bone-targeted delivery

Area of Science:

• Biomaterials Science
• Nanomedicine
• Drug Delivery Systems

Background:

• Bone-related diseases and cancers present significant treatment challenges.
• Current therapies often lack specificity, leading to substantial off-target side effects.
• There is a critical need for advanced drug delivery systems targeting bone tissue.

Purpose of the Study:

• To develop and characterize a novel bone-targeted liposomal formulation.
• To enhance drug delivery specifically to bone mineral (hydroxyapatite).
• To evaluate the efficacy and safety profile of the targeted liposomes compared to non-targeted ones.

Main Methods:

• Functionalization of liposomes with a pyrophosphate-cholesterol derivative to create Bone Binding Liposomes (BBL).
• Comparative binding affinity studies of BBL versus conventional Non-Binding Liposomes (NBL) to hydroxyapatite.
• Encapsulation of a prototype drug within both BBL and NBL formulations.
• Assessment of drug-loaded liposome biocompatibility and preservation of drug properties on target cells (macrophages).

Main Results:

• BBL demonstrated significantly superior binding affinity to bone mineral compared to NBL.
• Both BBL and NBL formulations efficiently encapsulated the prototype drug.
• Comparable biocompatibility was observed for both BBL and NBL.
• The drug's physicochemical properties were preserved on macrophages when delivered via both liposomal formulations.

Conclusions:

• Bone Binding Liposomes (BBL) represent a promising advancement in targeted drug delivery for bone conditions.
• The pyrophosphate-cholesterol functionalization effectively enhances liposome affinity for bone mineral.
• This targeted approach has the potential to improve therapeutic outcomes for bone diseases and cancers by increasing drug concentration at the target site and minimizing systemic toxicity.